medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-16-35-40medalphabet-2143Research ArticleСтатьиВозможности персонифицированного подхода к генно-инженерной биологической терапии ревматоидного артритаPossibilities of personalized approach to genetically engineered biological therapy of rheumatoid arthritishttps://orcid.org/0000-0002-0438-8554ШиловаЛ. Н.ShilovaL. N.

Шилова Людмила Николаевна, д.м.н., доцент, зав. кафедрой госпитальной, военно-полевой терапии

Shilova Lyudmila N., DM Sci, associate professor, head of Dept of Hospital, Military and Field Therapy

https://orcid.org/0000-0001-5127-611XСпицинаС. С.SpitsinaS. S.

Спицина Светлана Сергеевна, м.н.с., ассистент кафедры госпитальной, военно-полевой терапии

Spitsina Svetlana S., research assistant, assistant at Dept of Hospital, Military and Field Therapy

ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииРоссияVolgograd State Medical UniversityRussian FederationФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава России; ФГБНУ «Научно-исследовательский институт клинической и экспериментальной ревматологии имени А.Б. Зборовского»РоссияVolgograd State Medical University; A. B. Zborovsky Research Institute of Clinical and Experimental RheumatologyRussian Federation202118082021016Ревматология в общей врачебной практике3540Copyright © Шилова Л.Н., Спицина С.С., 20212021Шилова Л.Н., Спицина С.С.Shilova L.N., Spitsina S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2143

Ревматоидный артрит– наиболее частое ревматическое заболевание, характеризующееся поражением синовиальной оболочки, прогрессирующей деструкцией хрящевой и костной ткани. В результате установления биологической роли цитокинов стало возможным вмешательство в главные звенья патогенеза заболевания, что привело к торможению основного патологического процесса при РА – аутоиммунного воспаления.

Цель обзора

Цель обзора. Рассмотрение возможностей оптимизации биологической терапии ревматоидного артрита путем выявления предикторов противовоспалительной эффективности среди клинико-лабораторных маркеров.

Основные положения

Основные положения. Несмотря на успех генно-инженерных биологических препаратов в лечении воспалительных артритов, из-за отсутствия прогностических биомаркеров неизбежно применение подхода проб иошибок, эмпирической терапии, что не всегда приводит к удовлетворительным результатам. Исследование основных биомаркеров РА позволяет по-новому взглянуть на их потенциальную связь с различными клиническими фенотипами.

Заключение

Заключение. Такой подход, ориентированный на пациента, открывает перспективу улучшения результатов лечения за счет использования конкретных препаратов в определенных группах пациентов.

Rheumatoid arthritis is the most common rheumatic disease characterized by damage to the synovium, progressive destruction of cartilage and bone tissue. As a result of the establishment of the biological role of cytokines, it became possible to intervene in the main links of the pathogenesis of the disease, which led to inhibition of the main pathological process in RA – autoimmune inflammation.

The aim

The aim. To consider the possibilities of optimizing the biological therapy of rheumatoid arthritis by identifying predictors of anti-inflammatory efficacy among clinical and laboratory markers.

Basic provisions

Basic provisions. Despite the success of genetically engineered biological drugs in the treatment of inflammatory arthritis, due to the lack of predictive biomarkers, the use of a trial and error approach, empirical therapy, is inevitable, which does not always lead to satisfactory results. The study of the main biomarkers of RA provides new insights into their potential association with various clinical phenotypes.

Conclusion

Conclusion. This patient-centered approach offers the prospect of improving treatment outcomes through the use of specific drugs in certain patient groups.

ревматоидный артритбиологическая терапияпредикторы эффективностицитокиныrheumatoid arthritisbiological therapyefficiency predictorscytokinesReferencesАлександрова Е.Н., Новиков А.А., Насонов Е.Л. Роль биомаркеров в диагностике и прогнозировании эффективности современной терапии ревматоидного артрита. Клиническая лабораторная диагностика. 2013; (8): 3–13.Alexandrova E.N., Novikov A.A., Nasonov E.L. The role of biomarkers in the diagnosis and prediction of the effectiveness of modern therapy for rheumatoid arthritis. Clinical laboratory diagnostics. 2013; (8): 3–13.Pitzalis C., Choy EHS, Buch M.H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 2020 Oct; 16 (10): 590–599. DOI: 10.1038/s41584–020–0491–4.Pitzalis C., Choy EHS, Buch M.H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 2020 Oct; 16 (10): 590–599. DOI: 10.1038/s41584–020–0491–4.Ehrenstein M.R., Evans J.G., Singh A. et al. Compromised function of regulatory T-cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J. Exp. Med. 2004; 200: 77–85.Ehrenstein M.R., Evans J.G., Singh A. et al. Compromised function of regulatory T-cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J. Exp. Med. 2004; 200: 77–85.Bodman-Smith M.D., Corrigall V.M., Berglin E. et al. Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology (Oxford). 2004; 43: 1283–7.Bodman-Smith M.D., Corrigall V.M., Berglin E. et al. Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology (Oxford). 2004; 43: 1283–7.European Medicines Agency. Guideline on similar biological medicinal products. 2014.European Medicines Agency. Guideline on similar biological medicinal products. 2014.Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann. Rheum. Dis. 2011 Jan; 70 (1): 4–7. DOI: 10.1136/ard.2010.135376.Isaacs J.D., Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann. Rheum. Dis. 2011 Jan; 70 (1): 4–7. DOI: 10.1136/ard.2010.135376.Tanaka T., Hishitani Y., Ogata A. Monoclonal antibodies in rheumatoid arthritis: com parative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: targets & therapy. 2014; 8: 141.Tanaka T., Hishitani Y., Ogata A. Monoclonal antibodies in rheumatoid arthritis: com parative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: targets & therapy. 2014; 8: 141.Baji P., Pentek M., Czirjak L., et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur. J. Health. Econ. 2014; 15 (Suppl 1): S53–64. DOI: 10.1007/s10198–014–0594–4.Baji P., Pentek M., Czirjak L., et al. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur. J. Health. Econ. 2014; 15 (Suppl 1): S53–64. DOI: 10.1007/s10198–014–0594–4.Denisov L., Gordeev I., Mazurov V., et al. Comparison of efficacy, safety and phar macokinetics of infliximab biosimilar (BCD 055) and innovator infliximab. Annals of the Rheumatic Diseases. 2017; 76: 560–561.Denisov L., Gordeev I., Mazurov V., et al. Comparison of efficacy, safety and phar macokinetics of infliximab biosimilar (BCD 055) and innovator infliximab. Annals of the Rheumatic Diseases. 2017; 76: 560–561.Коротаева Т.В., Самцов А.В., Бакулев А.Л. и др. Сравнительная эффективность и безопасность биоаналога адалимумаба (BCD 057) и оригинального адалиму маба у пациентов с вульгарным псориазом. Результаты BCD 057–2 / CALYPSO – международного многоцентрового рандомизированного двойного слепого кли нического исследования III фазы. Современная ревматология. 2018; 12 (4): 71–84.Korotaeva T.V., Samtsov A.V., Bakulev A.L., et al. Comparative efficacy and safety of adalimumab biosimilar (BCD 057) and innovator in patients with psoriasis vulgaris. Results of the BCD 057–2 / CALYPSO phase III international, multicenter, randomized double-blind clinical trial. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018; 12 (4): 7 1–84 (in Russ.)Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 2010; 10: 308–15.Taylor P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 2010; 10: 308–15.Dhillon S., Lyseng-Williamson K.A., Scott L. J. Etanercept. A review of its use in the management of rheumatoid arthritis. Drugs. 2007; 67: 1211–41.Dhillon S., Lyseng-Williamson K.A., Scott L. J. Etanercept. A review of its use in the management of rheumatoid arthritis. Drugs. 2007; 67: 1211–41.Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 2004; 6: R. 264–72.Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 2004; 6: R. 264–72.Bruns A., Nicaise-Roland P., Hayem G. et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibod ies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009; 76: 248–53.Bruns A., Nicaise-Roland P., Hayem G. et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibod ies in patients with long-standing rheumatoid arthritis. Joint Bone Spine. 2009; 76: 248–53.Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006; 45: 1558–65.Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006; 45: 1558–65.Kristensen L.E., Kapetanovic M.C., Gülfe A., et al. Predictors of response to anti-TNF ther apy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008; 47: 495–9.Kristensen L.E., Kapetanovic M.C., Gülfe A., et al. Predictors of response to anti-TNF ther apy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008; 47: 495–9.Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010; 62: 22–32.Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010; 62: 22–32.Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J. Rheumatol. 2007; 34: 1670–3.Mancarella L., Bobbio-Pallavicini F., Ceccarelli F., et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J. Rheumatol. 2007; 34: 1670–3.Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann. Rheum. Dis. 2008; 67: 1139–44.Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann. Rheum. Dis. 2008; 67: 1139–44.Drynda S., Gloetzner M., Polter J., et al. Prediction of therapy response in anti-TNFa treated RA patients based on the identification of biomarkers. Arthritis Rheum. 2008; 58 (Suppl 9): S211.Drynda S., Gloetzner M., Polter J., et al. Prediction of therapy response in anti-TNFa treated RA patients based on the identification of biomarkers. Arthritis Rheum. 2008; 58 (Suppl 9): S211.Аронова Е.С. Применение инфликсимаба в реальной клинической практике: Автореф. дис. … к.м.н. М., 2012.Aronova E.S. The use of infliximab in real clinical practice: Abstract of the thesis. dis. … Ph D.M., 2012.Fabre S., Dupuy A.M., Dossat N. et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin. Exp. Immunol. 2008; 153: 188–95.Fabre S., Dupuy A.M., Dossat N. et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin. Exp. Immunol. 2008; 153: 188–95.Meliha Crnkic M., Mansson B., Larsson L. et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthr. Res. Ther. 2003; 5: R181–R185.Meliha Crnkic M., Mansson B., Larsson L. et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthr. Res. Ther. 2003; 5: R181–R185.Насонов Е.Л., Зонова Е.В., Иванова О.Н. и др. Результаты сравнительного клини ческого исследования III фазы препаратов ритуксимаба (Ацеллбия и Мабтера) при ревматоидном артрите (исследование BIORA). Научно-практическая рев матология. 2016; 54 (5): 510–9.Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia and MabThera) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016; 54 (5): 510–9 (In Russ.)Александрова Е.Н., Авдеева А.С., Лукина Г.В., Новиков А.А., Черкасова М.В., Попкова Т.В. и др. Клинико-иммунологические эффекты анти-В-клеточной тера пии у больных ревматоидным артритом. Науч.-практич. ревматол. 2012; 1: 14–21.Alexandrova E.N., Avdeeva A.S., Lukina G.V., Novikov A.A., Cherkasova M.V., Pop kova T.V. et al. Clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Scientific and Practical Rheumatol. 2012; 1: 14–21.Blom M., Wenink M., Huijbens R. et al. Altered сirculating cytokine pattern after ad ministration of rituximab is correlated with response to therapy in rheumatoid arthritis. Arthritis Rheum. 2008; 58: 450.Blom M., Wenink M., Huijbens R. et al. Altered сirculating cytokine pattern after ad ministration of rituximab is correlated with response to therapy in rheumatoid arthritis. Arthritis Rheum. 2008; 58: 450.Thurlings R.M., Boumans M.J.H., Vos K. et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to rituximab treatment in rheumatoid arthritis. Arthritis Rheum. 2009; 60 (Suppl.): 630 (1686).Thurlings R.M., Boumans M.J.H., Vos K. et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to rituximab treatment in rheumatoid arthritis. Arthritis Rheum. 2009; 60 (Suppl.): 630 (1686).Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54: 1390–400.Emery P., Fleischmann R., Filipowicz-Sosnowska A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54: 1390–400.Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis re fractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54: 279–806.Cohen S.B., Emery P., Greenwald M.W., et al. Rituximab for rheumatoid arthritis re fractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54: 279–806.Tak P.P., Cohen S., Emery P., et al. Baseline autoantibody status (RF, Anti-CCP) and clinical re sponse following the first treatment course with rituximab. Arthritis Rheum. 2006; 54 (Suppl 9): S368.Tak P.P., Cohen S., Emery P., et al. Baseline autoantibody status (RF, Anti-CCP) and clinical re sponse following the first treatment course with rituximab. Arthritis Rheum. 2006; 54 (Suppl 9): S368.Mariette X., Kivitz A., Isaacs J.D., et al. Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease char acteristics associated with poor outcomes. Arthritis Rheum. 2009; 60 (Suppl 10): S631.Mariette X., Kivitz A., Isaacs J.D., et al. Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (pts) with early active rheumatoid arthritis (RA) and disease char acteristics associated with poor outcomes. Arthritis Rheum. 2009; 60 (Suppl 10): S631.Ferraccioli G., Tolusso B., Bobbio-Pallavicini F., et al. Biomarkers predictors of good EULAR response to B-cell depletion therapy (BCDT) in seropositive Rheumatoid Arthritis Patients. Arthritis Rheum. 2010; 62 (Suppl); 1098.Ferraccioli G., Tolusso B., Bobbio-Pallavicini F., et al. Biomarkers predictors of good EULAR response to B-cell depletion therapy (BCDT) in seropositive Rheumatoid Arthritis Patients. Arthritis Rheum. 2010; 62 (Suppl); 1098.Fabris M., Quartuccio L., Saracco M., et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum. 2009; 60 (Suppl 10): S627.Fabris M., Quartuccio L., Saracco M., et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum. 2009; 60 (Suppl 10): S627.Nishimoto N., Yoshizaki K., Maeda K. et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 2003; 30: 1426–35.Nishimoto N., Yoshizaki K., Maeda K. et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 2003; 30: 1426–35.Авдеева А.С., Александрова Е.Н., Панасюк Е.Ю., Новиков А.А., Черкасова М.В., Насонов Е.Л. Влияние терапии тоцилизумабом наиммунологические показатели у больных ревматоидным артритом. Науч.-практич. ревматол. 2012; 50 (3): 25–32.Avdeeva A.S., Alexandrova E.N., Panasyuk E. Yu., Novikov A.A., Cherkasova M.V., Nasonov E.L. The effect of tocilizumab therapy on immunological parameters in pa tients with rheumatoid arthritis. Scientific and Practical Rheumatol. 2012; 50 (3): 25–32.Yamana J., Iwahashi M., Kim M. et al. T-cell-related cytokines are inhibited in response to tocilizumab in patients with rheumatYamana J., Iwahashi M., Kim M. et al. T-cell-related cytokines are inhibited in response to tocilizumab in patients with rheumatTanaka H., Kanazawa M., Kawakami T. et al. Efficacy and safety of tocilizumab therapy in rheumatoid arthritis: prevalence and predictive factors of sustained remission. Ann. Rheum. Dis. 2013; 72 (Suppl. 3): 453.Tanaka H., Kanazawa M., Kawakami T. et al. Efficacy and safety of tocilizumab therapy in rheumatoid arthritis: prevalence and predictive factors of sustained remission. Ann. Rheum. Dis. 2013; 72 (Suppl. 3): 453.Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., Takei S., Tanaka Y., Sano Y., Yaguramaki H., Yamanaka H. Effectiveness and safety of tocilizumab: postmar keting surveillance of 7901 patients with rheumatoid arthritis in Japan. J. Rheumatol. 2014 Jan; 41 (1): 15–23. DOI: 10.3899/jrheum.130466.Koike T., Harigai M., Inokuma S., Ishiguro N., Ryu J., Takeuchi T., Takei S., Tanaka Y., Sano Y., Yaguramaki H., Yamanaka H. Effectiveness and safety of tocilizumab: postmar keting surveillance of 7901 patients with rheumatoid arthritis in Japan. J. Rheumatol. 2014 Jan; 41 (1): 15–23. DOI: 10.3899/jrheum.130466.Pers Y.M., Schaub R., Constant E., Lambert J., Godfrin-Valnet M., Fortunet C., Bourichi W., Prades B.P., Wendling D., Gaudin P., Jorgensen C., Maillefert J.F., Marotte H. Effi cacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015 Jan; 82 (1): 25–30.Pers Y.M., Schaub R., Constant E., Lambert J., Godfrin-Valnet M., Fortunet C., Bourichi W., Prades B.P., Wendling D., Gaudin P., Jorgensen C., Maillefert J.F., Marotte H. Effi cacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015 Jan; 82 (1): 25–30.Genovese M.C., Fleischmann R., Kivitz A. J., et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheumatol. 2015; 67 (6): 1424–37.Genovese M.C., Fleischmann R., Kivitz A. J., et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheumatol. 2015; 67 (6): 1424–37.Raimondo M.G., Biggioggero M., Crotti C., Becciolini A., Favalli E.G. Profile of sarilum ab and its potential in the treatment of rheumatoid arthritis. Drug Des. Devel. Ther. 2017. 24; 11: 1593–1603. DOI: 10.2147/DDDT.S100302.Raimondo M.G., Biggioggero M., Crotti C., Becciolini A., Favalli E.G. Profile of sarilum ab and its potential in the treatment of rheumatoid arthritis. Drug Des. Devel. Ther. 2017. 24; 11: 1593–1603. DOI: 10.2147/DDDT.S100302.Takeuchi T., Tanaka Y., Yamanaka H., Amano K., Nagamine R., Park W., Shiozawa K., Tsukano M., Wei J.C., Shao J., Togo O., Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod. Rheumatol. 2016; 26 (1): 15–23.Takeuchi T., Tanaka Y., Yamanaka H., Amano K., Nagamine R., Park W., Shiozawa K., Tsukano M., Wei J.C., Shao J., Togo O., Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod. Rheumatol. 2016; 26 (1): 15–23.Gottenberg J.E., Ravaud P., Cantagrel A., Combe B., Flipo R.M., Schaeverbeke T. et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann. Rheum. Dis. 2012; 71: 1815–9.Gottenberg J.E., Ravaud P., Cantagrel A., Combe B., Flipo R.M., Schaeverbeke T. et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann. Rheum. Dis. 2012; 71: 1815–9.Russell A., Emery P., Kafka S.P. et al. Abatacept improves clinical responses regard less of baseline physical functions: results from the AIM trial. Arthr. Rheum. 2005; 52 (Suppl.): 543.Russell A., Emery P., Kafka S.P. et al. Abatacept improves clinical responses regard less of baseline physical functions: results from the AIM trial. Arthr. Rheum. 2005; 52 (Suppl.): 543.Fujii T., Sekiguchi M., Matsui K. et al. Very high titer of anti-citrullinated protein an tibodies is associated with the achievement of clinical remission by abatacept in biologic-naive patients with rheumatoid arthritis (the ABROAD study). Ann. Rheum. Dis. 2013; 72 (suppl. 3): 889.Fujii T., Sekiguchi M., Matsui K. et al. Very high titer of anti-citrullinated protein an tibodies is associated with the achievement of clinical remission by abatacept in biologic-naive patients with rheumatoid arthritis (the ABROAD study). Ann. Rheum. Dis. 2013; 72 (suppl. 3): 889.Simon T.A., Boers M., Hochberg M., Baker N., Skovron M.L., Ray N., Singhal S., Suissa S., Gomez-Caminero A. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res. Ther. 2019; 21 (1): 228Simon T.A., Boers M., Hochberg M., Baker N., Skovron M.L., Ray N., Singhal S., Suissa S., Gomez-Caminero A. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Res. Ther. 2019; 21 (1): 228

The authors declare that there are no conflicts of interest present.